Vaccine Market by Technology (Live, Conjugate, Toxoid, Recombinant), Disease (Influenza, DTaP, HPV, Hepatitis, Rotavirus, TT, Polio, MMR, Varicella, Dengue, TB, Rabies), Route (IM, SC, ID, Oral), End User (Pediatric, Adult) & Type - Forecast to 2022

The vaccines market is expected to reach USD 49.27 Billion by 2022 from USD 32.31 Billion in 2016 at a CAGR of 7.5%.

The objectives of this study are as follows:

• To define, describe, and forecast the vaccine market by technology, type, disease indication, route of administration, end user, and region
• To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, restraints, and industry-specific challenges)
• To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the market
• To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
• To forecast the size of the market segments with respect to four main regions, namely, North America, Europe, Asia, and the Rest of the World (RoW)
• To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies
• To track and analyze competitive developments such as mergers and acquisitions, product developments, partnerships, agreements and collaborations, expansions, and R&D activities in the vaccines market

Research Methodology

The study estimates the vaccines market size for 2017 and projects its demand till 2022. In the primary research process, various sources from both demand side and supply side were interviewed to obtain qualitative and quantitative information for the report. Primary sources from the demand side include various industry CEOs, vice presidents, marketing directors, technology and innovation directors, and related key executives from the various players in the vaccine market. For the market estimation process, both top-down and bottom-up approaches were used to estimate and validate the market size of the global market as well as to estimate the market size of various other dependent submarkets. All possible parameters that affect the market covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. This data was consolidated and added to detailed inputs and analysis from MarketsandMarkets and presented in this report.

To know about the assumptions considered for the study, download the pdf brochure

The vaccines market is highly competitive with the presence of various players. Some of the major players operating in the market are GlaxoSmithKline, plc (U.K.), Pfizer, Inc. (U.S.), Merck & Co., Inc. (U.S.), Sanofi Pasteur SA (France), Astellas Pharma Inc. (Japan), CSL Limited (Australia), Emergent BioSolutions, Inc. (U.S.), Johnson & Johnson (U.S.), MedImmune, LLC (U.S.), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo (Japan), Protein Sciences Corporation (U.S.), and Panacea Biotec (India).

Target Audience for this Report:

• Manufacturers and suppliers of vaccines
• Research and development companies
• Medical research laboratories
• Academic medical centers and universities
• Research and consulting firms
• Venture capital firms

Scope of the Report

This report categorizes the vaccine market into following segments and subsegments:

Vaccines Market, By Technology

• Conjugate Vaccines
• Inactivated and Subunit Vaccines
• Live Attenuated Vaccines
• Toxoid Vaccines
• Recombinant Vaccines

Vaccines Market, By Type

• Monovalent Vaccines
• Multivalent Vaccines

Vaccines Market, By Disease Indication

• Pneumococcal Disease
• Influenza
• DTP
• Hepatitis
• Human Papilloma Virus (HPV)
• Rotavirus
• Meningococcal Disease
• MMR (measles, mumps, and rubella)
• Varicella
• Polio
• Dengue
• Other Disease Indications

Vaccines Market, By Route of Administration

• Intramuscular and Subcutaneous Administration
• Oral Administration
• Other Routes of Administration

Vaccines Market, By End User

• Pediatrics
• Adults

Vaccines Market, By Region

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe (RoE)
• Asia
  • Japan
  • China
  • India
  • Rest of Asia (RoA)
• Rest of the World (RoW)

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company‘s specific needs.

The following customization options are available for this report.

Company Information

Detailed analysis and profiling of additional market players (up to 5)

Table of Contents

1 Introduction (Page No. - 17)
    1.1 Objectives of the Study
    1.2 Market Definition
    1.3 Market Scope
           1.3.1 Market Covered
           1.3.2 Years Considered for the Study
    1.4 Currency
    1.5 Limitation
    1.6 Market Stakeholders

2 Research Methodology (Page No. - 21)
    2.1 Secondary Data
    2.2 Primary Data
    2.3 Key Industry Insights
    2.4 Market Size Estimation
    2.5 Market Breakdown and Data Triangulation
    2.6 Market Share Estimation
    2.7 Assumptions for the Study

3 Executive Summary (Page No. - 30)

4 Premium Insights (Page No. - 34)
    4.1 Overview of the Vaccines Market
    4.2 Global Market, By Type, 2017–2022
    4.3 Global Market, By End User, 2017 vs 2022 (USD Billion)
    4.4 Geographic Analysis: Global Market, By Technology
    4.5 Global Market, By Route of Administration, 2017 vs 2022 (USD Billion)
    4.6 Geographical Snapshot of the Global Market

5 Market Overview (Page No. - 38)
    5.1 Introduction
    5.2 Market Dynamics
           5.2.1 Drivers
                    5.2.1.1 High Prevalence of Infectious Diseases
                    5.2.1.2 Rising Focus on Immunization Programs
                    5.2.1.3 Growing Government Support for Vaccine Development
                    5.2.1.4 Increasing Company Investments Into Vaccine R&D
           5.2.2 Restraints
                    5.2.2.1 High Cost of Vaccine Development
                    5.2.2.2 Product Recalls
           5.2.3 Opportunities
                    5.2.3.1 High Growth Prospects in Emerging Markets
                    5.2.3.2 Focus on Therapeutic Vaccines
                    5.2.3.3 Use of Adjuvants in Vaccines
           5.2.4 Challenges
                    5.2.4.1 Inadequate Access to Vaccines
           5.2.5 Burning Issues
                    5.2.5.1 Vaccine Pricing

6 Industry Insights (Page No. - 46)
    6.1 Investment Analysis
    6.2 Regulatory Landscape
           6.2.1 North America
           6.2.2 Europe
           6.2.3 Asia
           6.2.4 RoW
    6.3 Key Pipeline Products
    6.4 New Vaccine Opportunities
           6.4.1 HIV
                    6.4.1.1 HIV Vaccine: Product Pipeline
                    6.4.1.2 HIV Vaccine: Public-Private Initiatives
                    6.4.1.3 HIV Vaccine: Funding
           6.4.2 Malaria
                    6.4.2.1 Malaria Vaccine: Product Pipeline
                    6.4.2.2 Malaria Vaccine: Public-Private Initiatives
           6.4.3 Zika
                    6.4.3.1 Zika Vaccine: Product Pipeline
                    6.4.3.2 Zika Vaccine: Public-Private Initiatives
                    6.4.3.3 Zika Vaccine: Funding
           6.4.4 Ebola
                    6.4.4.1 Ebola Vaccine: Product Pipeline
                    6.4.4.2 Ebola Vaccine: Public-Private Initiatives
                    6.4.4.3 Ebola Vaccine: Funding

7 Vaccine Market, By Technology (Page No. - 60)
    7.1 Introduction
    7.2 Conjugate Vaccines
    7.3 Inactivated and Subunit Vaccines
    7.4 Live Attenuated Vaccines
    7.5 Recombinant Vaccines
    7.6 Toxoid Vaccines

8 Vaccine Market, By Type (Page No. - 68)
    8.1 Introduction
    8.2 Monovalent Vaccines
    8.3 Multivalent Vaccines

9 Vaccine Market, By Disease Indication (Page No. - 73)
    9.1 Introduction
    9.2 Pneumococcal Disease
    9.3 DTP
    9.4 Influenza
    9.5 Human Papilloma Virus
    9.6 Meningococcal Disease
    9.7 Polio
    9.8 Rotavirus
    9.9 Hepatitis
    9.10 MMR
    9.11 Varicella
    9.12 Dengue
    9.13 Other Disease Indications

10 Vaccine Market, By Route of Administration (Page No. - 90)
     10.1 Introduction
     10.2 Intramuscular and Subcutaneous Administration
     10.3 Oral Administration
     10.4 Other Routes of Administration

11 Vaccine Market, By End User (Page No. - 95)
     11.1 Introduction
     11.2 Pediatrics
     11.3 Adults

12 Vaccine Market, By Region (Page No. - 100)
     12.1 Introduction
     12.2 North America
             12.2.1 U.S.
             12.2.2 Canada
     12.3 Europe
             12.3.1 Germany
             12.3.2 U.K.
             12.3.3 France
             12.3.4 Italy
             12.3.5 Spain
             12.3.6 Rest of Europe (RoE)
     12.4 Asia
             12.4.1 Japan
             12.4.2 China
             12.4.3 India
             12.4.4 Rest of Asia (RoA)
     12.5 Rest of the World (RoW)

13 Competitive Landscape (Page No. - 130)
     13.1 Introduction
     13.2 Market Share Analysis
     13.3 Competitive Leadership Mapping
             13.3.1 Visionary Leaders
             13.3.2 Innovators
             13.3.3 Dynamic Differentiators
             13.3.4 Emerging Companies
     13.4 Strength of Product Portfolio (For 25 Players)
     13.5 Business Strategy Excellence (For 25 Players)

*Top 25 Companies Analyzed for This Studies are - Pfizer, Inc., Glaxosmithkline PLC., Merck & Co., Inc., Sanofi Pasteur SA, CSL Limited, Emergent Biosolutions, Inc., Johnson & Johnson, Medimmune, LLC, Astellas Pharma Inc., Serum Institute of India, Bavarian Nordic, Mitsubishi Tanabe Pharma Corporation, Protein Science Corporation, Daiichi Sankyo Company, Limited, Abbott Laboratories, Panacea Biotec, Paxvax, Inc., Zydus Cadila, Green Cross Corporation, Valneva Se, Indian Immunologicals Limited, Incepta Vaccine Ltd., Sinovac Biotech Ltd., Vbi Vaccines Inc., Pt Bio Farma (Persero)

14 Company Profiles (Page No. - 136)
(Overview, Products Offered, Product Offering Scorecard, Business Strategy Scorecard, Recent Developments)*
     14.1 Pfizer, Inc.
     14.2 Glaxosmithkline PLC.
     14.3 Merck & Co., Inc.
     14.4 Sanofi Pasteur SA
     14.5 CSL Limited
     14.6 Emergent Biosolutions, Inc.
     14.7 Johnson & Johnson
     14.8 Medimmune, LLC (A Subsidiary of Astrazeneca)
     14.9 Astellas Pharma, Inc.
     14.10 Serum Institute of India
     14.11 Bavarian Nordic
     14.12 Mitsubishi Tanabe Pharma Corporation
     14.13 Daiichi Sankyo Company, Limited
     14.14 Protein Sciences Corporation
     14.15 Panacea Biotec

*Details on Marketsandmarkets View, Overview, Products Offered, Product Offering Scorecard, Business Strategy Scorecard, and Recent Developments Might Not Be Captured in Case of Unlisted Companies.

15 Appendix (Page No. - 196)
     15.1 Insights of Industry Experts
     15.2 Discussion Guide
     15.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
     15.4 Introducing RT: Real-Time Market Intelligence
     15.5 Available Customizations
     15.6 Related Reports
     15.7 Author Details

List of Tables (92 Tables)

Table 1 Incidence of Diseases, 2015
Table 2 Nih Funding for Vaccine Research, 2012-2017 (USD Million)
Table 3 Immunization Coverage, By Disease, 2014 vs 2015
Table 4 Regulatory Authorities in Europe
Table 5 Regulatory Authorities in Asia
Table 6 Key Pipeline Vaccines
Table 7 Estimated Investment in HIV Vaccines, By Investor (2015–2016)
Table 8 Ebola Projects Funded By European Commission (2014–2020)
Table 9 Vaccines Market, By Technology, 2015–2022 (USD Million)
Table 10 Cost of Meningococcal Conjugate Vaccines
Table 11 Conjugate Vaccines Market, By Region, 2015–2022 (USD Million)
Table 12 Examples of Inactivated and Subunit Vaccines
Table 13 Inactivated and Subunit Vaccines Market, By Region, 2015–2022 (USD Million)
Table 14 Live Attenuated Vaccines Market, By Region, 2015–2022 (USD Million)
Table 15 Examples of Recombinant Vaccines
Table 16 Recombinant Vaccines Market, By Region, 2015–2022 (USD Million)
Table 17 Toxoid Vaccines Market, By Region, 2015–2022 (USD Million)
Table 18 Vaccines Market, By Type, 2015–2022 (USD Million)
Table 19 Monovalent Vaccines Market, By Region, 2015–2022 (USD Million)
Table 20 Examples of Notable Multivalent Vaccines Available in the Market
Table 21 Multivalent Vaccines Market, By Region, 2015–2022 (USD Million)
Table 22 Vaccines Market, By Disease Indication, 2015–2022 (USD Million)
Table 23 List of Commercially Available Pneumococcal Vaccines in the Market
Table 24 Global Market for Pneumococcal Disease, By Region, 2015–2022 (USD Million)
Table 25 List of Commercially Available DTP Vaccines in the Market
Table 26 Global Market for DTP, By Region, 2015–2022 (USD Million)
Table 27 List of Commercially Available Influenza Vaccines in the Market
Table 28 Global Market for Influenza, By Region, 2015–2022 (USD Million)
Table 29 List of Commercially Available HPV Vaccines in the Market
Table 30 Vaccines Market for HPV, By Region, 2015–2022 (USD Million)
Table 31 List of Commercially Available HPV Vaccines in the Market
Table 32 Market for Meningococcal Disease, By Region, 2015–2022 (USD Million)
Table 33 List of Commercially Available Polio Vaccines in the Market
Table 34 Market for Polio, By Region, 2015–2022 (USD Million)
Table 35 List of Commercially Available Rotavirus Vaccines in the Market
Table 36 Market for Rotavirus, By Region, 2015–2022 (USD Million)
Table 37 List of Commercially Available Hepatitis Vaccines in the Market
Table 38 Vaccines Market for Hepatitis, By Region, 2015–2022 (USD Million)
Table 39 List of Commercially Available MMR Vaccines in the Market
Table 40 Global Market for MMR, By Region, 2015–2022 (USD Million)
Table 41 List of Commercially Available Varicella Vaccines in the Market
Table 42 Global Market for Varicella, By Region, 2015–2022 (USD Million)
Table 43 List of Commercially Available Vaccines for Other Disease Indications in the Market
Table 44 Vaccines Market for Other Disease Indications, By Region, 2015–2022 (USD Million)
Table 45 Market, By Route of Administration, 2015–2022 (USD Million)
Table 46 Market for Intramuscular and Subcutaneous Administration, By Region, 2015–2022 (USD Million)
Table 47 Market for Oral Administration, By Region, 2015–2022 (USD Million)
Table 48 Market for Other Routes of Administration, By Region, 2015–2022 (USD Million)
Table 49 Vaccines Market Size, By End User, 2015–2022 (USD Million)
Table 50 Pediatric Vaccines Market, By Region, 2015–2022 (USD Million)
Table 51 North America: Pediatric Vaccines Market, By Country, 2015–2022 (USD Million)
Table 52 Adult Vaccines Market, By Region, 2015–2022 (USD Million)
Table 53 North America: Adult Vaccines Market, By Country, 2015–2022 (USD Million)
Table 54 Market, By Region, 2015–2022 (USD Million)
Table 55 North America: Vaccines Market, By Country, 2015–2022 (USD Million)
Table 56 North America: Vaccine Market, By Technology, 2015–2022 (USD Million)
Table 57 North America: Market, By Type, 2015–2022 (USD Million)
Table 58 North America: Market, By Disease Indication, 2015–2022 (USD Million)
Table 59 North America: Market, By Route of Administration, 2015–2022 (USD Million)
Table 60 North America: Market, By End User, 2015–2022 (USD Million)
Table 61 U.S.: Vaccines Market, By Technology, 2015–2022 (USD Million)
Table 62 U.S.: Vaccine Market, By End User, 2015–2022 (USD Million)
Table 63 Canada: Vaccines Market, By Technology, 2015–2022 (USD Million)
Table 64 Canada: Vaccine Market, By End User, 2015–2022 (USD Million)
Table 65 Europe: Vaccines Market, By Country, 2015–2022 (USD Million)
Table 66 Europe: Vaccine Market, By Technology, 2015–2022 (USD Million)
Table 67 Europe: Market, By Type, 2015–2022 (USD Million)
Table 68 Europe: Market, By Disease Indication, 2015–2022 (USD Million)
Table 69 Europe: Market, By Route of Administration, 2015–2022 (USD Million)
Table 70 Europe: Market, By End User, 2015–2022 (USD Million)
Table 71 Germany: Vaccines Market, By Technology, 2015–2022 (USD Million)
Table 72 U.K.: Vaccine Market, By Technology, 2015–2022 (USD Million)
Table 73 France: Market, By Technology, 2015–2022 (USD Million)
Table 74 Italy: Market, By Technology, 2015–2022 (USD Million)
Table 75 Spain: Market, By Technology, 2015–2022 (USD Million)
Table 76 RoE: Market, By Technology, 2015–2022 (USD Million)
Table 77 Asia: Health Expenditure Per Capita, By Country, 2000 & 2014 (USD)
Table 78 Asia: Vaccines Market, By Country, 2015–2022 (USD Million)
Table 79 Asia: Vaccine Market, By Technology, 2015–2022 (USD Million)
Table 80 Asia: Market, By Type, 2015–2022 (USD Million)
Table 81 Asia: Market, By Disease Indication, 2015–2022 (USD Million)
Table 82 Asia: Market, By Route of Administration, 2015–2022 (USD Million)
Table 83 Asia: Market, By End User, 2015–2022 (USD Million)
Table 84 Japan: Vaccines Market, By Technology, 2015–2022 (USD Million)
Table 85 China: Market, By Technology, 2015–2022 (USD Million)
Table 86 India: Vaccine Market, By Technology, 2015–2022 (USD Million)
Table 87 RoA: Vaccines Market, By Technology, 2015–2022 (USD Million)
Table 88 RoW: Vaccines Market, By Technology, 2015–2022 (USD Million)
Table 89 RoW: Market, By Type, 2015–2022 (USD Million)
Table 90 RoW: Market, By Disease Indication, 2015–2022 (USD Million)
Table 91 RoW: Market, By Route of Administration, 2015–2022 (USD Million)
Table 92 RoW: Market, By End User, 2015–2022 (USD Million)

List of Figures (52 Figures)

Figure 1 Vaccines Market Segmentation
Figure 2 Research Design
Figure 3 Key Data From Secondary Sources
Figure 4 Key Data From Primary Sources
Figure 5 Vaccines Market Size Estimation: Bottom-Up Approach
Figure 6 Market Size Estimation: Top-Down Approach
Figure 7 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 8 Data Triangulation Methodology
Figure 9 Vaccines Market, By Technology, 2017–2022
Figure 10 Vaccine Market, By Type, 2017 vs 2022 (USD Billion)
Figure 11 Vaccines Market, By Disease Indication, 2017 vs 2022 (USD Billion)
Figure 12 Vaccine Market, By Route of Administration, 2017 vs 2022 (USD Billion)
Figure 13 Vaccines Market, By End User, 2017 vs 2022 (USD Billion)
Figure 14 Geographical Snapshot of the Global Market
Figure 15 High Prevalence of Diseases and Rising Government & Nongovernment Funding for Vaccine Development—Primary Growth Drivers for the Vaccines Market
Figure 16 Monovalent Vaccines to Register the Highest Growth Rate in the Forecast Period
Figure 17 Pediatrics Segment Will Continue to Dominate the Vaccines Market in 2022
Figure 18 Conjugate Vaccines to Account for the Largest Share of the Vaccines Market in 2017
Figure 19 Intramuscular and Subcutaneous Administration Segment to Witness the Highest Growth Rate in the Forecast Period
Figure 20 U.S. to Dominate the Vaccines Market in 2017
Figure 21 Vaccine Market: Drivers, Restraints, Opportunities, and Challenges
Figure 22 Major Investors in the Global Vaccines Market
Figure 23 Vaccine Funding, By Investor, 2014
Figure 24 Gavi Vaccine Funding, By Type of Investor, 2014
Figure 25 Gavi Forecast Vaccine Expenditure, By Disease, 2016–2020
Figure 26 Regulatory Approval Process for Vaccines
Figure 27 R&D Funding for HIV Preventive Vaccines, By Investor, 2014
Figure 28 Conjugate Vaccines Segment to Dominate the Vaccine Technologies Market During the Forecast Period
Figure 29 Monovalent Vaccines to Dominate the Vaccines Market in 2017
Figure 30 Pneumococcal Disease Segment Will Continue to Dominate the Vaccines Market in 2022
Figure 31 Global Vaccines Market for Dengue, 2015–2022 (USD Million)
Figure 32 Intramuscular and Subcutaneous Administration Segment Will Continue to Dominate the Global Vaccines Market in 2022
Figure 33 Pediatrics End-User Segment to Dominate the Global Vaccines Market in 2017
Figure 34 North America: Vaccines Market Snapshot, 2017
Figure 35 Europe: Vaccines Market Snapshot, 2017
Figure 36 Asia: Vaccines Market Snapshot, 2017
Figure 37 RoW: Vaccines Market Snapshot, 2017
Figure 38 Vaccines Market Share Analysis, By Key Player, 2016
Figure 39 Vaccines Market (Global) Competitive Leadership Mapping, 2017
Figure 40 Pfizer, Inc.: Company Snapshot
Figure 41 Glaxosmithkline PLC.: Company Snapshot
Figure 42 Merck & Co., Inc.: Company Snapshot
Figure 43 Sanofi Pasteur SA: Company Snapshot
Figure 44 CSL Limited: Company Snapshot
Figure 45 Emergent Biosolutions: Company Snapshot
Figure 46 Johnson & Johnson: Company Snapshot
Figure 47 Astrazeneca: Company Snapshot
Figure 48 Astellas Pharma, Inc.: Company Snapshot
Figure 49 Bavarian Nordic: Company Snapshot
Figure 50 Mitsubishi Tanabe Pharma Corporation: Company Snapshot
Figure 51 Daiichi Sankyo Company, Limited: Company Snapshot
Figure 52 Panacea Biotec: Company Snapshot (2016)

The vaccines market is expected to reach USD 49.27 Billion by 2022 from USD 34.30 Billion in 2017, at a CAGR of 7.5%. Factors such as rising prevalence of diseases, increasing government and nongovernment funding for vaccine development, and increasing investments by companies are driving the vaccine market.

This report segments the vaccines market into technology, type, disease indication, route of administration, end user, and region. Based on technology, the vaccine market is segmented into conjugate vaccines, inactivated and subunit vaccines, live attenuated vaccines, recombinant vaccines, and toxoid vaccines. The conjugate vaccines segment is expected to account for the largest share of the global market, in 2017.

Based on the end user, the vaccines market is segmented into pediatrics and adults. The adult segment is expected to register the highest CAGR during the forecast period. Factors like the increasing investments by companies for the development of new adult vaccines and government initiatives for immunization are driving the growth of this segment.

In 2017, North America is expected to dominate the market, followed by Europe. The high growth of the North American market is attributed to the factors such as increasing investments by government organizations and companies to promote immunization as well as develop new vaccines.

While North America is expected to dominate the market in 2017, Asia is expected to register the highest CAGR during the forecast period. The high growth in this market is attributed to increasing investments by companies in the emerging countries of the Asian region such as India and China and rising disposable income.

While the vaccines market presents significant growth opportunities, market growth may be hindered due to the high cost of vaccine development and product recalls. The vaccine market is highly competitive with several big and small players. Prominent players in the market include Astellas Pharma Inc. (Japan), CSL Limited (Australia), Emergent BioSolutions, Inc. (U.S.), GlaxoSmithKline, plc (U.K.), Johnson & Johnson (U.S.), MedImmune, LLC (U.S.), Merck & Co., Inc. (U.S.), Pfizer, Inc. (U.S.), Sanofi Pasteur SA (France), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo (Japan), Protein Sciences Corporation (U.S.), and Panacea Biotec (India).

To speak to our analyst for a discussion on the above findings, click Speak to Analyst